Share on facebook Share on Twitter Share on Google Plus Share This

Cancer Moonshot 2020 Pediatrics Consortium

A patient of pediatric hematology/oncology at Floating Hospital for Children in Boston.The Personalized Cancer Care Program at Floating Hospital for Children has set it sails towards the Cancer Moonshot 2020, in order to reach our ultimate destination in making childhood cancer a more managable and controlable disease. As one of the 10 founding members of the Pediatric Consortium, we are committed to apply the most comprehensive cancer molecular diagnostic testing available—integrating whole genomic and proteomic analysis and leverage proven and promising combination immunotherapies and clinical trials. The Cancer Moonshot 2010 will implement real time data sharing infrastructure in order to accelerate clinical learning and insight to all consortium members.

“This is the most exciting time in oncology. For the first time in many decades, we have the tools and understanding to abandon the old paradigm of killing cancer and develop more individualized, rational, and much less toxic approaches,” desribes Giannoula Lakka Klement, MD, director of the Personalized Cancer Program.

The Floating Hospital has been using proetomic and genomic diagnosistic testing to create and treat patients with individualized  combinatory molecular therapies for since 2010.  By coupling combination molecular therapies with low dose metronomic chemotherapy, we are able to minimize  side-effects while maintaining treatment response. We are excited to expand our local vision to a national level with the Cancer Moonshot 2020 collaboration.

Dr. Klement specializes in molecular therapeutics and the treatment of brain tumors, rare tumors and vascular anomalies. Her laboratory research encompasses tumor and wound angiogenesis, with emphasis on the role of platelets in angiogenesis. As one of the founders of metronomic chemotherapy, Dr. Klement has positioned Floating Hospital for Children as leader changing the paradigm of cancer into a treatable disease.

Cancer MoonShot 2020 is the nation's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit or watch the video below.

Founding Members in the Cancer MoonShot 2020 Pediatrics Consortium are:

1. Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago IL 
2. Children’s Healthcare of Atlanta, GA, Aflac Cancer & Blood Disorders Center 
3. Children’s Hospital of Orange County, CA 
4. Children’s Hospital of Philadelphia, PA 
5. Children’s Hospital of Pittsburgh of UPMC, PA 
6. Duke Department of Pediatrics – Duke University School of Medicine, NC 
7. Floating Hospital for Children at Tufts Medical Center, MA 
8. Huntsman Cancer Institute at the University of Utah and Intermountain Primary Children’s Hospital, UT 
9. Phoenix Children’s Hospital, AZ 
10. Sanford Health, SD

A union of forces is needed to successfully implement this opportunity of combinatorial immunotherapies in the war against cancer. The goal is to obtain a commitment by members of the National Immunotherapy Coalition to collectively address the obstacles that may impede rapid clinical implementation of the QUILT Program, by collectively addressing the following issues:

1. Validation of Big Science: Complex science involving the human immune system and the validation of the safety and efficacy of combination therapy must be tested by reputable scientific enterprises in an unbiased manner without any prejudices other than the interest of the patient. 

2. Access to novel agents and approved drugs: One of the major challenges facing rapid progress in this field is that numerous pharmaceutical and biotech companies each have their own immunotherapeutic agents in the form of antibodies, immune cells, and vaccines in preclinical and clinical studies. 

3. FDA Regulation: Novel approaches for the adaptive combination of novel agents in this new paradigm where the combined multi-agents serve as a systems biological approach to the treatment of cancer. 

4. Care coordination and real-time monitoring of safety and outcomes with integration of complex molecular data, phenotypic data obtained from disparate electronic records. 

5. Ability to measure outcomes and cost in real time to enable payors to pay for value rather than procedures and establish an adaptive learning system for enhanced predictive modeling.

6. Network Infrastructure: Highly Secure Bandwidth to Transmit Big Data & Interrogate complex molecular information in large scale. 

Goal: To validate the potential of combination immunotherapy as the next generation standard of care in cancer patients by completing randomized Phase II trials in patients at all stages of disease in up to 20 tumor types in 20,000 patients, within the next 24-months. These findings will inform Phase III trials and the Moonshot to Develop a Vaccine Based Immunotherapy for Cancer by 2020.

The QUILT Program

A Quantitative Integrative Lifelong Trial in patients with cancer undergoing next generation panomic analysis (genome, proteome, immunome and metabolome) to inform precise cancer care based on individualized and dynamic biology of the disease. The protocols will be designed to harness all the elements of the immune system (dendritic, T-Cell, and NK Cell) to combine vaccines and cell based immunotherapy with metronomic chemotherapy and immunomodulators with the goal of durable, long-lasting remission of the disease with the highest quality of life.